Atracor

Atracor Special Precautions

atracurium besilate

Manufacturer:

Hana

Distributor:

Endure Medical
Full Prescribing Info
Special Precautions
In common with all the other neuromuscular blocking agents, atracurium paralyses the respiratory muscles as well as other skeletal muscles but has no effect on consciousness. Atracurium should be administered only with adequate general anesthesia and only by or under the close supervision of an experienced anesthetist with adequate facilities for endotracheal intubation and artificial ventilation.
The potential for histamine release exists in susceptible patients during atracurium administration. Caution should be exercised in administering atracurium to patients with history suggestive of an increased sensitivity to the effects of histamine. In particular, bronchospasm may occur in patients with a history of allergy and asthma.
High rates of cross-sensitivity between neuromuscular blocking agents have been reported. Therefore, where possible, before administering atracurium, hypersensitivity to other neuromuscular blocking agents should be excluded. Atracurium should only be used when absolutely essential in susceptible patients. Patients who experience a hypersensitivity reaction under general anesthesia should be tested subsequently for hypersensitivity to other neuromuscular blockers.
Monitoring of serial creatinine phosphate (CPK) values should be considered in asthmatic patients receiving high dose corticosteroids and neuromuscular blocking agents in ICU.
Atracurium does not have significant vagal or ganglionic blocking properties in the recommended dosage range. Consequently, atracurium has no clinically significant effects on heart rate in the recommended dosage range and it will not counteract the bradycardia produced by many anesthetic agents or by vagal stimulation during surgery.
In common with other non-depolarizing neuromuscular blocking agents, increased sensitivity to atracurium may be expected in patients with myasthenia gravis and other forms of neuromuscular disease.
As with other neuromuscular blocking agents, severe acid-base and/or serum electrolyte abnormalities may increase or decrease the sensitivity of patients to atracurium.
As with other non-depolarizing neuromuscular blockers, hypophosphatemia may prolong recovery. Recovery may be hastened by correcting this condition.
Atracurium should be administered over a period of 60 seconds to patients  who may be unusually sensitive to falls in arterial blood pressure, for example those who are hypovolemic.
Atracurium is inactivated by high pH and so must not be mixed in the same syringe with thiopental or any alkaline agent.
When a small vein is selected as the injection site, atracurium should be flushed through the vein with physiological saline after injection.
When other anesthetic drugs are administered through the same in-dwelling needle or cannula as atracurium, it is important that each drug is flushed through with an adequate volume of physiological saline. Atracurium besilate is hypotonic and must not be administered into the infusion line of a blood transfusion.
Studies in malignant hyperthermia in susceptible animals (swine), and clinical studies in patients susceptible to malignant hypothermia indicate that atracurium does not trigger this syndrome.
In common with other non-depolarizing neuromuscular blocking agents, resistance may develop in patients suffering from burns.
Such patients may require increased doses, dependent on the time elapsed since the burn injury and the extent of the burn.
Intensive Care Unit (ICU) patients: When administered to laboratory animals in high doses, Laudanosine, a metabolite of atracurium has been associated with transient hypotension and in some species, cerebral excitatory effects. Although seizures have been seen in ICU patients receiving atracurium, a causal relationship to laudanosine has not been established.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in